Detailed explanation of the efficacy, role and treatment indications of avatrombopag (Su Kexin)

1. Drug Overview and Mechanism of Action

Avatrombopag (Avatrombopag) is a new oral small molecule thrombopoietin receptor agonist (TPO-RA). It binds to the c-Mpl receptor on the surface of hematopoietic stem cells and megakaryocytes, simulating the effect of endogenous thrombopoietin, thereby promoting the proliferation, differentiation and maturation of megakaryocytes, and ultimately accelerating the production of platelets. Compared with platelet transfusion, avatrombopag is a treatment idea that "stimulates endogenous production", thus avoiding the problems of immune rejection, infection transmission, and insufficient platelet supply that may be caused by exogenous platelet transfusion.

In addition, as a second-generation TPO-RA, avatrombopag’s structural characteristics determine that it does not need to interact with multivalent cations in food, unlike eltrombopag (Eltrombopag) which requires strict fasting or avoidance of dairy products, so it has high patient compliance and convenience in life.

2. Main functions and clinical efficacy

The core function of avatrombopag is Effectively increase platelet levels and reduce the risk of bleeding. In clinical studies, platelet levels are usually significantly increased within a few days to a week after taking avatrombopag. The increase is stable and sustainable, making it suitable for long-term use. In multiple international clinical trials, avatrombopag has shown significant efficacy in patients with chronic immune thrombocytopenia (ITP), with more than 60% of patients able to achieve thrombocytopenia. Plate count ≥50×10⁹/L, and significantly reduce bleeding events such as skin bleeding and nosebleeds.

In terms of safety, avatrombopag was generally well tolerated. Common side effects include headache, fatigue, nausea, etc., but most are mild to moderate and controllable. Compared with some TPO-RA drugs, avatrombopag does not show an obvious risk of abnormal liver function, and no significant tendency of myelofibrosis has been found, which provides a safety guarantee for long-term treatment.

3. Approved therapeutic indications

At present, avatrombopag has been approved in many countries and regions. Its main indications include:

1.Chronic immune thrombocytopenia (ITP): Suitable for adult patients who are ineffective or intolerant to conventional treatments (such as glucocorticoids, immunoglobulins). For these patients, avatrombopag can significantly increase platelet counts and reduce the risk of severe bleeding, making it a long-term second-line treatment option.

2. Thrombocytopenia before elective surgery in patients with chronic liver disease: These patients often suffer from thrombocytopenia due to liver dysfunction, and direct surgery may easily cause severe bleeding. Avatrombopag can be used short-term before surgery to effectively increase platelet levels, reduce the risks and inconvenience caused by platelet transfusion, and ensure the smooth progress of the surgery.

In China, avatrombopag has been approved for marketing by the State Food and Drug Administration and is mainly used for the treatment of adult patients with chronic ITP. This means that domestic patients with thrombocytopenia have an additional oral and convenient treatment option.

4. Comparison with otherTPO-RA drugs

Avatrombopag has similarities in its mechanism of action with eltrombopag (Eltrombopag), lumipros (Romiplostim), etc.TPO-RA, but there are certain differences in actual use:

1. Mode of administration: Both avatropopag and eltrombopag are oral preparations, while lumipros requires subcutaneous injection. In comparison, avatropopag is more convenient.

2. Dietary compliance: During the medication process of eltrombopag, it is necessary to avoid interference from multivalent ions such as dairy products, iron supplements, and calcium supplements. However, avatrombopag does not have such restrictions and can be taken with food, which improves the convenience of medication.

3.Safety: Eltrombopag can cause liver function abnormalities in some patients, but avitrombopag did not show obvious liver toxicity in clinical trials and is better tolerated.

4.Onset of effect: All three can increase platelets in the short term, but avatrombopag usually takes effect faster and has relatively small fluctuations, which is conducive to clinical monitoring and management.

5. Potential expanded applications and research directions

Although the current approved indications for avatrombopag are limited to ITP and chronic liver disease-related thrombocytopenia, studies are currently exploring its application prospects in the fields of chemotherapy-related thrombocytopenia and myelodysplastic syndrome-related thrombocytopenia. Some early studies have shown that avatrombopag can also stably increase platelet levels in these diseases and reduce transfusion dependence due to thrombocytopenia.

In addition, due to its good oral compliance and tolerability, the use of avatrombopag in the pediatric ITP population is also being studied and may be expanded to a wider patient population in the future.

6. Clinical significance and patient value

For patients with thrombocytopenia, long-term bleeding risks and repeated blood transfusions bring huge physical and psychological burdens. The emergence of avatrombopag provides these patients with an oral, convenient, safe and effective treatment option. Especially in the management of chronic ITP, avatrombopag can reduce patients' dependence on blood transfusions and high-intensity immunosuppressive therapy, significantly improving quality of life.

Under the guidance of clinicians, the individualized medication regimen of avatrombopag can balance efficacy and safety, control platelet levels, and avoid the risk of thrombosis caused by excessive elevation. Taken together, avatrombopag not only improves the treatment landscape of thrombocytopenia, but also brings new hope for the clinical treatment of blood diseases and liver diseases.

Reference materials:https://www.drugs.com/